DNX-2401 pembrolizumab
Showing 1 - 25 of 1,483
Brain Cancer, Brain Tumor, Glioma Trial in Canada, United States (DNX-2401, pembrolizumab)
Completed
- Brain Cancer
- +10 more
- DNX-2401
- pembrolizumab
-
Little Rock, Arkansas
- +14 more
Jul 13, 2021
Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)
Recruiting
- Melanoma
- Pembrolizumab
- +5 more
-
Los Angeles, California
- +39 more
Jan 25, 2023
NSCLC Trial in Worldwide (biological, drug, radiation)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- pembrolizumab/vibostolimab
- +7 more
-
Hollywood, Florida
- +29 more
Aug 22, 2022
Stomach Tumors Trial in China (Pembrolizumab, Cisplatin, 5-fluorouracil)
Withdrawn
- Stomach Neoplasms
- Pembrolizumab
- +5 more
-
Beijing, Beijing, China
- +27 more
Dec 15, 2021
Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer Trial in Tampa (DNX-2440)
Recruiting
- Liver Metastases
- +10 more
- DNX-2440
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute, Inc.
Mar 28, 2022
Triple Negative Breast Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Carboplatin)
Active, not recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab
- +3 more
-
Monterey, California
- +121 more
Oct 10, 2022
Small Cell Lung Cancer Trial in Worldwide (biological, drug, radiation)
Recruiting
- Small Cell Lung Cancer
- Pembrolizumab 200 mg
- +8 more
-
Chandler, Arizona
- +170 more
Feb 2, 2023
Small Cell Lung Cancer Trial in Worldwide (Pembrolizumab, MK-4830, MK-5890)
Recruiting
- Small Cell Lung Cancer
- Pembrolizumab
- +6 more
-
Gilbert, Arizona
- +48 more
Jan 19, 2023
Metastatic NSCLC Trial in Worldwide (Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin)
Recruiting
- Metastatic Non-Small Cell Lung Cancer
- Pembrolizumab/Vibostolimab
- +6 more
-
Colorado Springs, Colorado
- +134 more
Jan 27, 2023
Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)
Recruiting
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- +9 more
-
Mobile, Alabama
- +194 more
Aug 18, 2022
Endometrial Tumors Trial in Worldwide (pembrolizumab, carboplatin, paclitaxel)
Recruiting
- Endometrial Neoplasms
- pembrolizumab
- +4 more
-
Miami Beach, Florida
- +106 more
Aug 11, 2022
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Tumors Trial in Worldwide (Pembrolizumab, Placebo for pembrolizumab,
Active, not recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +7 more
-
Birmingham, Alabama
- +226 more
Aug 22, 2022
Small Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab Co-Formulation, Saline , Etoposide)
Recruiting
- Small Cell Lung Carcinoma
- Pembrolizumab/Vibostolimab Co-Formulation
- +5 more
-
Los Angeles, California
- +122 more
Jan 27, 2023
Metastatic Hormone-Sensitive Prostate Cancer Trial in Worldwide (biological, drug, procedure, other)
Active, not recruiting
- Metastatic Hormone-Sensitive Prostate Cancer
- Pembrolizumab
- +3 more
-
Anchorage, Alaska
- +212 more
Aug 18, 2022
Breast Tumors Trial in Worldwide (pembrolizumab, paclitaxel, nab-paclitaxel)
Recruiting
- Breast Neoplasms
- pembrolizumab
- +6 more
-
Tucson, Arizona
- +188 more
Aug 11, 2022
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma Trial in
Recruiting
- Endometrial Clear Cell Adenocarcinoma
- +17 more
- Carboplatin
- +5 more
-
Birmingham, Alabama
- +376 more
Aug 24, 2022
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,
Not yet recruiting
- Cervical Cancer
- +2 more
- PRGN-2009 plus Pembrolizumab
- Pembrolizumab alone
-
Bethesda, MarylandNational Institute of Health
Nov 27, 2023
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023
Carcinoma, Renal Cell Trial in China (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)
Recruiting
- Carcinoma, Renal Cell
- Pembrolizumab
- +3 more
-
Beijing, Beijing, China
- +16 more
Jun 2, 2023
Triple Negative Breast Cancer, Neoadjuvant Chemo, Pembrolizumab Trial in Seoul (Visium, Whole Genome Sequencing(WGS)/Whole
Recruiting
- Triple Negative Breast Cancer
- +3 more
- Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 15, 2023
NSCLC Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Non-small Cell Lung Cancer
- V940
- +2 more
- (no location specified)
Oct 5, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Triple Negative Breast Tumors Trial (Pembrolizumab injection, Capecitabine tablets, Local radiotherapy)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Pembrolizumab injection
- +2 more
- (no location specified)
Jul 25, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023